Top

Annals of Nuclear Medicine

Published in:

Open Access 01-01-2019 | Original Article

Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis

Authors: Mahmudur G. M. Rahman, Muhammad M. Islam, Tetsuya Tsujikawa, Yasushi Kiyono, Hidehiko Okazawa

Published in: Annals of Nuclear Medicine | Issue 1/2019

Abstract

Objective

To calculate the specific binding ratio (SBR) appropriately in dopamine transporter (DAT) imaging, a method for extracting the striatal volume of interest (VOI) was developed.

Methods

This study included 200 patients (72 ± 10 years) who were suspected of parkinsonian syndromes (PS) or dementia with Lewy body (DLB). The patients were divided into three groups of PS with dopaminergic degeneration, DLB and non-PS after [¹²³I]ioflupane (FP-CIT) SPECT and clinical follow-up. The image data were reconstructed with CT attenuation correction and scatter correction, and with only CT attenuation correction (CTAC). The new method extracted striatal VOI according to the high-level counts and the average striatum volume, and calculated SBR using the reference occipital counts. The SBR values for each patient were obtained using the Tossici-Bolt method (SBR_Bolt) and our method. Reproducibility of SBR calculation using our method was compared by two operators.

Results

The mean SBR values for the PS and DLB groups were significantly different from that of the non-PS group with both methods. The coefficients of variation of the SBR were significantly smaller with the proposed method compared with those of SBR_Bolt (p < 0.001), except for the CTAC images. There were no differences in SBR between the two operators using our method. The diagnostic accuracies with our method for the PS and DLB groups were 98.4 and 96.0%, respectively.

Conclusion

Our new method for SBR calculation in the FP-CIT SPECT showed less coefficients of variation with high reproducibility, which would be useful for clinical diagnosis and in assessing the severity of diseases in follow-up studies.

Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with ¹²³I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692–8.CrossRefPubMed

Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (¹²³I-ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22:2346–51.CrossRefPubMed

Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5–12.CrossRefPubMed

Covington MF, Sherman S, Lewis D, Lei H, Krupinski E, Kuo PH. Patient survey on satisfaction and impact of ¹²³I-ioflupane dopamine transporter imaging. PLoS One. 2015;10(7):e0134457.CrossRefPubMedPubMedCentral

Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109–18.PubMed

Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderate advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl Med Commun. 2001;22:721–5.CrossRefPubMed

Booij J, Speelman JD, Horstink MWIM, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [¹²³I]FPCIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72.CrossRefPubMed

Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653–61.CrossRef

Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.CrossRefPubMed

10.

Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [¹²³I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2013;40:565–73.CrossRefPubMed

11.

Tossici-Bolt L, Hoffmann S, Kemp P, Mehta R, Fleming J. Quantification of [¹²³I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med. 2006;33:1491–9.CrossRef

12.

Neishi H, Ikawa M, Okazawa H, Tsujikawa T, Arishima H, Kikuta K, Yoneda M. Precise evaluation of striatal oxidative stress corrected for severity of dopaminergic neuronal degeneration in patients with Parkinson’s disease: a study with ⁶²Cu-ATSM PET and ¹²³I-FP-CIT SPECT. Eur Neurol. 2017;78:161–8.CrossRefPubMed

13.

Blinkov SM, Glezer II. The human brain in figures and tables. A quantitative handbook. New York: Basic Books; 1968. pp. 166–71.

14.

Aylward EH, Li Q, Habbak R, Warren A, Pulsifer MB, Barta PE, Jerram M, Pearlson G. Basal ganglia volume in adults with Down syndrome. Psychiatry Res. 1997;74:73–82.CrossRefPubMed

15.

Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiat. 2012;83:620–28.CrossRefPubMed

16.

Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using ¹²³I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50.CrossRefPubMed

17.

Djang DS, Janssen MJ, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with ¹²³I-ioflupane SPECT 1.0. J Nucl Med. 2012;53:154–63.CrossRefPubMed

18.

Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38:1529–40.CrossRefPubMed

19.

Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, et al. Reduction in camera-specific variability in [¹²³I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. Eur J Nucl Med Mol Imaging. 2016;43:1323–36.CrossRefPubMed

20.

Nonokuma M, Kuwabara Y, Hida K, Tani T, Takano K, Yoshimitsu K. Optimal ROI setting on the anatomically normalized I-123 FP-CIT images using high-resolution SPECT. Ann Nucl Med. 2016;30:637–44.CrossRefPubMedPubMedCentral

21.

Mizumura S, Nishikawa K, Murata A, Yoshimura K, Ishii N, Kokubo T, et al. Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count. Ann Nucl Med. 2018;32:288–96.CrossRefPubMed

22.

Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. CLE differentiation of dementia with lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73:130–40.

23.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AGM, et al. [¹²³I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:133–40.CrossRefPubMedPubMedCentral

24.

Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporter with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39:1879–84.PubMed

25.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RB, Charney DS, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and Parkinson’s patients. J Nucl Med. 1998;39:1500–8.PubMed

26.

van Dyck CH, Seibyl JP, Malison RT, Laurelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med. 1995;36:1175–81.PubMed

27.

Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging. 2011;38:764–73.CrossRefPubMed

28.

Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St. George-Hyslop PH, Raphael D, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med. 1998;39:1511–8.PubMed

29.

Schwarz J, Storch A, Koch W, Pogarelli O, Radau PE, Tatsch K. Loss of dopamine transporter binding follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694–7.PubMed

30.

Tsuchida T, Ballinger JR, Vines D, Kim YJ, Utsunomiya K, Lang AE, et al. Reproducibility of dopamine transporter density measured with ¹²³I-FPCIT SPECT in normal control and Parkinson’s disease patients. Ann Nucl Med. 2004;18:609–16.CrossRefPubMed

31.

Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [¹²³I]-β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158–67.CrossRefPubMed

32.

Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with ¹²³I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000;41:36–44.PubMed

33.

Crespo C, Gallego J, Cot A, Falcón C, Bullich S, Pareto D, Aguiar P, Sempau J, Lomeña F, Calviño F, Pavía J, Ros D. Quantification of dopaminergic neurotransmission SPECT studies with ¹²³I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. Eur J Nucl Med Mol Imaging. 2008;35:1334–42.CrossRefPubMed

34.

Kupitz D, Apostolova I, Lange C, Ulrich G, Amthauer H, Brenner W, et al. Global scaling for semi-quantitative analysis in FP-CIT SPECT. Nuklearmedizin. 2014;53:234–41.CrossRefPubMed

Title: Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis
Authors: Mahmudur G. M. Rahman
Muhammad M. Islam
Tetsuya Tsujikawa
Yasushi Kiyono
Hidehiko Okazawa
Publication date: 01-01-2019
Publisher: Springer Singapore
Published in: Annals of Nuclear Medicine / Issue 1/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-018-1297-1

At a glance: The STEP trials

Springer Medicine

Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis

Abstract

Objective

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Advantages of 99mTc-3PRGD2 SPECT over CT in the preoperative assessment of lymph node metastasis in patients with esophageal cancer

The role of 13N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions

The significant value of predicting prognosis in patients with colorectal cancer using 18F-FDG PET metabolic parameters of primary tumors and hematological parameters

Techniques for generating attenuation map using cardiac SPECT emission data only: a systematic review

Comparison of 18F-Choline PET/CT and MRI functional parameters in prostate cancer

Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas